Immunocytokines are a promising immunotherapeutic approach against glioblastoma
The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Immunocytokines display promising antitumor activity in orthotopic mouse models of glioma and patients with glioblastoma.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Specific antibodies (such as L19) against fibronectin to improve tumor response in the clinical trials of patients with glioblastoma by localizing interleukin 2 (IL‐2) or interleukin 12 (IL‐12) in the tumor, leading to increased infiltration of cytotoxic T cells [81, 82, 83].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [81]
Citations
Cites
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“This might be the consequence of glioma cell–intrinsic factors, such as cell-to-cell heterogeneity (5) and the presence of too few immunogenic neoepitopes (6), as well as high levels of immunosuppressive cytokines (7) and immunosuppressive myeloid (8) and lymphoid (9) cell populations, which result in a strong immunos…”
BackgroundAn Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma
Neftel, C., Laffy, J., Filbin, M. G., Hara, T., Shore, M. E., Rahme, G. J., Richman, A. R., Silverbush, D., Shaw, M. L., Hebert, C. M., et al. (2019) · Cell · doi:10.1016/j.cell.2019.06.024 · Cited by 2,873
Ostrom, Q. T., Cioffi, G., Gittleman, H., Patil, N., Waite, K., Kruchko, C., & Barnholtz-Sloan, J. S. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz150 · Cited by 2,585
Reardon, D. A., Brandes, A. A., Omuro, A., Mulholland, P., Lim, M., Wick, A., Baehring, J., Ahluwalia, M. S., Roth, P., Bähr, O., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.1024 · Cited by 1,501
Self-citationWeller, M., Butowski, N., Tran, D. D., Recht, L. D., Lim, M., Hirte, H., Ashby, L., Mechtler, L., Goldlust, S. A., Iwamoto, F., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30517-x · Cited by 1,134
Self-citationWeller, M., van den Bent, M., Tonn, J. C., Stupp, R., Preusser, M., Cohen-Jonathan-Moyal, E., Henriksson, R., Rhun, E. L., Balana, C., Chinot, O., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30194-8 · Cited by 1,088
Self-citationThe making of bispecific antibodies
Brinkmann, U., & Kontermann, R. E. (2017) · mAbs · doi:10.1080/19420862.2016.1268307 · Cited by 923
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
Okada, H., Weller, M., Huang, R., Finocchiaro, G., Gilbert, M. R., Wick, W., Ellingson, B. M., Hashimoto, N., Pollack, I. F., Brandes, A. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00088-1 · Cited by 781
Self-citationChang, A. L., Miska, J., Wainwright, D. A., Dey, M., Rivetta, C. V., Yu, D., Kanojia, D., Pituch, K. C., Qiao, J., Pytel, P., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0144 · Cited by 640
Zardi, L., Carnemolla, B., Siri, A., Petersen, T. E., Paolella, G., Sebastio, G., & Baralle, F. E. (1987) · The EMBO Journal · doi:10.1002/j.1460-2075.1987.tb02509.x · Cited by 338
Carnemolla, B., Balza, E., Siri, A., Zardi, L., Nicotra, M. R., Bigotti, A., & Natali, P. G. (1989) · The Journal of cell biology · doi:10.1083/jcb.108.3.1139 · Cited by 335
Santimaria, M., Moscatelli, G., Viale, G. L., Giovannoni, L., Neri, G., Viti, F., Leprini, A., Borsi, L., Castellani, P., Zardi, L., et al. (2003) · PubMed · Cited by 335
Self-citationTargeting Interleukin 6 Signaling Suppresses Glioma Stem Cell Survival and Tumor Growth
Wang, H., Lathia, J. D., Wu, Q., Wang, J., Li, Z., Heddleston, J. M., Eyler, C. E., Elderbroom, J., Gallagher, J., Schuschu, J., et al. (2009) · Stem Cells · doi:10.1002/stem.188 · Cited by 333
Brain Tumor Microenvironment and Host State: Implications for Immunotherapy
Tomaszewski, W., Sanchez-Perez, L., Gajewski, T. F., & Sampson, J. H. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1627 · Cited by 319
Carnemolla, B., Borsi, L., Balza, E., Castellani, P., Meazza, R., Berndt, A., Ferrini, S., Kosmehl, H., Neri, D., & Zardi, L. (2002) · Blood · doi:10.1182/blood.v99.5.1659 · Cited by 296
Self-citationNKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma
Weiss, T., Weller, M., Guckenberger, M., Sentman, C. L., & Roth, P. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1788 · Cited by 287
Self-citationChiocca, E. A., Yu, J. S., Lukas, R. V., Solomon, I. H., Ligon, K. L., Nakashima, H., Triggs, D. A., Reardon, D. A., Wen, P., Stopa, B. M., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw5680 · Cited by 263
Fibronectin as target for tumor therapy
Kaspar, M., Zardi, L., & Neri, D. (2006) · International Journal of Cancer · doi:10.1002/ijc.21677 · Cited by 249
Self-citationStimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer types
Hong, I.-S. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.64 · Cited by 240
Selective targeted delivery of TNFα to tumor blood vessels
Borsi, L., Balza, E., Carnemolla, B., Sassi, F., Castellani, P., Berndt, A., Kosmehl, H., Birò, A., Siri, A., Orecchia, P., et al. (2003) · Blood · doi:10.1182/blood-2003-04-1039 · Cited by 234
Self-citationThe Toxicology of Interleukin-12: A Review
Car, B. D., Eng, V. M., Lipman, J. M., & Anderson, T. D. (1999) · Toxicologic Pathology · doi:10.1177/019262339902700112 · Cited by 220
Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell–mediated glioma rejection
vom Berg, J., Vrohlings, M., Haller, S., Haimovici, A., Kulig, P., Sledzinska, A., Weller, M., & Becher, B. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130678 · Cited by 213
Self-citationKohanbash, G., McKaveney, K., Sakaki, M., Ueda, R., Mintz, A. H., Amankulor, N., Fujita, M., Ohlfest, J. R., & Okada, H. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4124 · Cited by 191
Danielli, R., Patuzzo, R., Di Giacomo, A. M., Gallino, G., Maurichi, A., Di Florio, A., Cutaia, O., Lazzeri, A., Fazio, C., Miracco, C., et al. (2015) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-015-1704-6 · Cited by 177
Self-citationCrane, C. A., Ahn, B. J., Han, S. J., & Parsa, A. T. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos014 · Cited by 169
Halin, C., Gafner, V., Villani, M. E., Borsi, L., Berndt, A., Kosmehl, H., Zardi, L., & Neri, D. (2003) · PubMed · Cited by 168
Self-citationCastellani, P., Borsi, L., Carnemolla, B., Bíró, A., Dorcaratto, A., Viale, G. L., Neri, D., & Zardi, L. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64446-x · Cited by 158
Self-citationMohme, M., Schliffke, S., Maire, C. L., Rünger, A., Glau, L., Mende, K. C., Matschke, J., Gehbauer, C., Akyüz, N., Zapf, S., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2617 · Cited by 151
Distribution of laminin and fibronectin isoforms in oral mucosa and oral squamous cell carcinoma
Kosmehl, H., Berndt, A., Strassburger, S., Borsi, L., Rousselle, P., Mandel, U., Hyckel, P., Zardi, L., & Katenkamp, D. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690809 · Cited by 145
Immunocytokines for cancer treatment: past, present and future
Neri, D., & Sondel, P. M. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.03.006 · Cited by 145
Self-citationAntibody–Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity
Neri, D. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0622 · Cited by 136
Self-citationNKG2D-Dependent Antitumor Effects of Chemotherapy and Radiotherapy against Glioblastoma
Weiß, T., Schneider, H., Silginer, M., Steinle, A., Pruschy, M. N., Polić, B., Weller, M., & Roth, P. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1766 · Cited by 127
Self-citationGrünhagen, D. J., de Wilt, J. H., ten Hagen, T. L. M., & Eggermont, A. M. M. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0426 · Cited by 101
Lode, H. N., Xiang, R., Becker, J. C., Gillies, S. D., & Reisfeld, R. A. (1998) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00033-3 · Cited by 96
Spitaleri, G., Berardi, R., Pierantoni, C., Pas, T. M. D., Noberasco, C., Libbra, C., González‐Iglesias, R., Giovannoni, L., Tasciotti, A., Neri, D., et al. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1327-7 · Cited by 94
Self-citationGillies, S. D., Lan, Y., Wesolowski, J. S., Qian, X., Reisfeld, R. A., Holden, S. A., Super, M., & Lo, K.-M. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.12.6195 · Cited by 93
Papadia, F. S., Basso, V., Patuzzo, R., Maurichi, A., Florio, A. D., Zardi, L., Ventura, E., González‐Iglesias, R., Lovato, V., Giovannoni, L., et al. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23168 · Cited by 84
Self-citationRadretumab Radioimmunotherapy in Patients with Brain Metastasis: A 124I-L19SIP Dosimetric PET Study
Poli, G. L., Bianchi, C., Virotta, G., Bettini, A., Moretti, R., Trachsel, E., Elia, G., Giovannoni, L., Neri, D., & Bruno, A. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0007 · Cited by 78
Self-citationTMARKER: A free software toolkit for histopathological cell counting and staining estimation
Schüffler, P. J., Fuchs, T. J., Ong, C. S., Wild, P. J., Rupp, N. J., & Buhmann, J. M. (2013) · Journal of Pathology Informatics · doi:10.4103/2153-3539.109804 · Cited by 75
Young, P. A., Morrison, S. L., & Timmerman, J. M. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.08.002 · Cited by 66
Curran, C. S., Evans, M. D., & Bertics, P. J. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1001965 · Cited by 63
CISNE: An accurate description of dose-effect and synergism in combination therapies
García‐Fuente, A., Vázquez, F., Viéitez, J. M., Alonso, F. J. G., Martín, J. I., & Ferrer, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-23321-6 · Cited by 63
Puca, E., Probst, P., Stringhini, M., Murer, P., Pellegrini, G., Cazzamalli, S., Hutmacher, C., Gouyou, B., Wulhfard, S., Matasci, M., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32603 · Cited by 51
Self-citationImmunotherapy for glioblastoma: on the sidelines or in the game?
Reardon, D. A., Wucherpfennig, K. W., & Chiocca, E. A. (2017) · PubMed · Cited by 44
Ventura, E., Weller, M., Macnair, W., Eschbach, K., Beisel, C., Cordazzo, C., Claassen, M., Zardi, L., & Burghardt, I. (2017) · Journal of Cell Science · doi:10.1242/jcs.209619 · Cited by 40
Self-citationProbst, P., Stringhini, M., Ritz, D., Fugmann, T., & Neri, D. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1728 · Cited by 34
Self-citationDevelopment of a Function-Blocking Antibody Against Fibulin-3 as a Targeted Reagent for Glioblastoma
Nandhu, M. S., Behera, P., Bhaskaran, V., Longo, S. L., Barrera-Arenas, L. M., Sengupta, S., Rodriguez‐Gil, D. J., Chiocca, E. A., & Viapiano, M. S. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1628 · Cited by 33
Schneider, H., Szabó, E., Machado, R. A. C., Broggini‐Tenzer, A., Walter, A., Lobell, M., Heldmann, D., Süßmeier, F., Grünewald, S., & Weller, M. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13877 · Cited by 25
Self-citationA universal reporter cell line for bioactivity evaluation of engineered cytokine products
Mock, J., Pellegrino, C. E., & Neri, D. (2020) · Scientific Reports · doi:10.1038/s41598-020-60182-4 · Cited by 19
Self-citationCasanova, R., Xia, D., Rulle, U., Nanni, P., Grossmann, J., Vrugt, B., Wettstein, R., Ballester‐Ripoll, R., Astolfo, A., Weder, W., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2363 · Cited by 17
Xia, D., Casanova, R., Machiraju, D., McKee, T. D., Weder, W., Beck, A. H., & Soltermann, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-22254-4 · Cited by 17
Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study
Nowosielski, M., Gorlia, T., Bromberg, J. E. C., Sahm, F., Harting, I., Kickingereder, P., Brandes, A. A., TAPHOORN, M. J. B., Taal, W., Dômont, J., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007643 · Cited by 10
Self-citationSchmid, A. S., & Neri, D. (2019) · PLoS ONE · doi:10.1371/journal.pone.0219313 · Cited by 2
Self-citationA universal reporter cell line for bioactivity evaluation of engineered cytokine productsPreprint
Mock, J., Pellegrino, C. E., & Neri, D. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/739987 · Cited by 1
Self-citation
Cited by
Antibody–drug conjugates come of age in oncology
Dumontet, C., Reichert, J. M., Senter, P. D., Lambert, J. M., & Beck, A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00709-2 · Cited by 842
Weller, M., Wen, P. Y., Chang, S. M., Dirven, L., Lim, M., Monje, M., & Reifenberger, G. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00516-y · Cited by 592
Self-citationCurrent advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 558
Lin, H., Liu, C., Hu, A., Zhang, D., Yang, H., & Mao, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01544-7 · Cited by 392
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
Metadata
- Authors
- Weiss, T., Puca, E., Silginer, M., Hemmerle, T., Pazahr, S., Bink, A., Weller, M., Neri, D., & Roth, P.
- Affiliations
- University of Zurich (CH)
- ETH Zurich (CH)
- Philochem (Switzerland) (CH)
- Corresponding author
- Weiss, Tobias
- Puca, Emanuele
- Neri, Dario
- Roth, Patrick
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2020-10-07
- Volume
- 12
- Issue
- 564
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W3092445835
- Cited by
- 133
- References
- 54
- Citations by year
- 2026: 15 · 2025: 21 · 2024: 27 · 2023: 24 · 2022: 24 · 2021: 21 · 2020: 1
- FWCI
- 9.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Funders
- European Research Council (670603)
- Swiss National Science Foundation (SNF 310030_170027, 323630_164218, 310030_182003/1)
- Oncosuisse (KFS-4544-08-2018-R)
- Forschungskredit University of Zurich (FK-18-054)
- Swiss Cancer Research Foundation (MD-PhD-3558-06-2015)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- immunocytokines, glioblastoma, tumor-infiltrating lymphocytes, tumor microenvironment, inflammatory cytokines, adaptive immunity, tumor necrosis, CD4+ T cells, CD8+ T cells, tumor perfusion, immunotherapy
- MeSH terms
- Animals, Glioblastoma, Humans, Immunotherapy, Interleukin-2, Cytokines, CD8-Positive T-Lymphocytes, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.